1-3 of 3
Robert D. van Beek, MD
Close
Sort by
Journal Articles

Pharmacogenetic Risk Factors for Altered Bone Mineral Density and Body Composition in Pediatric Acute Lymphoblastic Leukemia.

Mariël L. te Winkel, MD, Robert D van Beek, MD, Sabine M.P.F. de Muinck Keizer-Schrama, MD, PhD, André G. Uitterlinden, Prof., Wim C.J. Hop, PhD, Rob Pieters, Prof., M.M. Van Den Heuvel, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 3071.
https://doi.org/10.1182/blood.V114.22.3071.3071
Published: 2009
Journal Articles

A Randomized Trial Investigating an Exercise Program to Prevent Osteoporosis and Motor Problems during Treatment for Childhood Acute Lymphoblastic Leukemia.

Mariel L. te Winkel, MD, Annelies Hartman, MSc, Robert D. van Beek, MD, Sabine M.P.F. de Muinck Keizer-Schrama, MD., PhD, Han C.G. Kemper, PhD, Wim C.J. Hop, PhD, Marry M. van den Heuvel-Eibrink, MD, PhD, Rob Pieters, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 912.
https://doi.org/10.1182/blood.V112.11.912.912
Published: 2008
Journal Articles

The C677T Polymorphism in the Methylenetetrahydrofolate Reductase (MTHFR)Gene Is an Important Determinant of Bone Mineral Density in Pediatric Acute Lymphoblastic Leukemia Patients.

Robert D. van Beek, MD, Sabine M.P.F. de Muinck Keizer-Schrama, MD, PhD, Robert de Jonge, MD, PhD, Rob Pieters, MD, PhD, Marry M. van den Heuvel-Eibrink, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 4434.
https://doi.org/10.1182/blood.V104.11.4434.4434
Published: 2004